20 patients with primarily inoperable squamous cell carcinoma of the head and neck were treated with 2 cycles of chemotherapy prior to surgical treatment. The lymphocyte subsets were determined prior to chemotherapy, as well as directly after and 3 weeks after start of each chemotherapy cycle. For this, 2 different flow cytometric techniques were used in parallel. After the second cycle of chemotherapy 10 patients were additionally treated with thymostimulin for 2 weeks. The remaining ten patients received no additional immunotherapy and served as control group. Three patients (one in the control group and two in the verum group) had to be excluded from the study because the immunological examination could not be performed in accordance with the protocol. In addition another patient had a local skin reaction so that thymostimulin therapy could not be started as allergy to bovine proteins was suspected. Prior to the first chemotherapy treatment, there is no detectable defect in the distribution of lymphocyte subsets. Under chemotherapy treatment the absolute number of Pan-T cells, T-helper cells, T-suppressor cells and Leu-10 positive B-cells decreased. In contrast, additional treatment with thymostimulin directly after the chemotherapeutic regimen resulted in a marked increase of all T-lymphocytes as well as the Leu-10-positive cells. The results measured with two different flow cytometric techniques were comparable.

Download full-text PDF

Source

Publication Analysis

Top Keywords

lymphocyte subsets
8
prior chemotherapy
8
flow cytometric
8
cytometric techniques
8
control group
8
chemotherapy treatment
8
chemotherapy
6
patients
5
[effect thymostimulin
4
thymostimulin chemotherapy-induced
4

Similar Publications

Cancer immunotherapies rely on CD8 cytolytic T lymphocytes (CTLs) in recognition and eradication of tumor cells via antigens presented on major histocompatibility complex class I (MHC-I) molecules. However, we observe MHC-I deficiency in human and murine urologic tumors, posing daunting challenges for successful immunotherapy. We herein report an unprecedented nanosonosensitizer of one-dimensional bamboo-like multisegmented manganese dioxide@manganese-bismuth vanadate (BMMBV) to boost multiple branches of immune responses targeting MHC-I-deficient tumors.

View Article and Find Full Text PDF

Regulatory T Cells for Stroke Recovery: A Promising Immune Therapeutic Strategy.

CNS Neurosci Ther

January 2025

Department of Research, Beijing Rehabilitation Hospital, Capital Medical University, Beijing, China.

Background: Stroke remains a leading cause of mortality and disability among adults. Given the restricted therapeutic window for intravascular interventions and neuroprotection during the acute phase, there has been a growing focus on tissue repair and functional recovery in the subacute and chronic phases after stroke. The pro-inflammatory microglial polarization occurs in subacute and chronic phases after stroke and may represent therapeutic targets for stroke recovery.

View Article and Find Full Text PDF

Prehabilitation of Patients With Oesophageal Malignancy Undergoing Peri-Operative Treatment (Pre-EMPT): Outcomes From a Prospective Controlled Trial.

J Surg Oncol

January 2025

Department of Upper GI and General Surgery, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom.

Background: The Pre-EMPT study aimed to determine if structured exercise could reduce length of stay, post-operative complications and improve fitness and health-related quality of life (HQRL) in patients undergoing neoadjuvant chemotherapy (NAC) and oesophagectomy.

Methods: A prospective non-randomised trial compared a standard care pathway (control) to a structured prehabilitation exercise programme (intervention) commenced before NAC and surgery for oesophageal adenocarcinoma. Length of hospital stay and post-operative complications were recorded.

View Article and Find Full Text PDF

Myricetin exposure reduces PC differentiation in vitro in primary human B cells.

Mol Med

January 2025

Center for Autoimmune Musculoskeletal and Hematopoietic Diseases, Institute of Molecular Medicine, The Feinstein Institutes for Medical Research, Northwell Health, 350 Community Drive, Manhasset, New York, 11030, USA.

Background: The process of B cell activation and plasma cell (PC) formation involves morphological, transcriptional, and metabolic changes in the B cell. Blocking or reducing PC differentiation is one approach to treat autoimmune diseases that are characterized by the presence of pathogenic autoantibodies. Recent studies have suggested the potential of myricetin, a natural flavonoid with anti-inflammatory and antioxidant properties, to block or reduce PC differentiation.

View Article and Find Full Text PDF

Background: Polyclonal autologous T cells that are epigenetically reprogrammed through mTOR inhibition and IFN-α polarization (RAPA-201) represent a novel approach to the adoptive T cell therapy of cancer. Ex vivo inhibition of mTOR results causes a shift towards T central memory (T) whereas ex vivo IFN-α promotes type I cytokines, with each of these functions known to enhance the adoptive T cell therapy of cancer. Rapamycin-resistant T cells polarized for a type II cytokine phenotype were previously evaluated in the allogeneic transplantation context.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!